DBV Technologies SA

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

29 Sep 2026 18:28:57 By Nasdaq GlobeNewswire

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

16 Jan 2026 18:11:36 By Nasdaq GlobeNewswire

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

12 Jan 2026 16:00:00 By Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

07 Jan 2026 16:00:00 By Nasdaq GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

05 Jan 2026 16:00:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

16 Dec 2025 16:05:00 By Nasdaq GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025

02 Dec 2025 16:00:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

11 Nov 2025 23:50:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

04 Nov 2025 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

03 Nov 2025 16:30:00 By Nasdaq GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

03 Nov 2025 16:25:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

30 Oct 2025 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

30 Oct 2025 03:00:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

29 Oct 2025 18:47:09 By Nasdaq GlobeNewswire

DBV Technologies Reports Third Quarter 2025 Financial Results

28 Oct 2025 16:25:00 By Nasdaq GlobeNewswire

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

06 Oct 2025 17:02:03 By Nasdaq GlobeNewswire

DBV Technologies Announces Resignation of Board Member

18 Sep 2025 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

05 Sep 2025 16:30:00 By Nasdaq GlobeNewswire

DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

03 Sep 2025 16:30:00 By Nasdaq GlobeNewswire

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025

01 Aug 2025 16:05:00 By Nasdaq GlobeNewswire